Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice

Core Insights - Pelthos Therapeutics Inc. has acquired Xeglyze® (abametapir) from Hatchtech Pty Ltd. for $1.8 million, enhancing its portfolio of FDA-approved therapeutic products [1][2][3] Company Overview - Pelthos Therapeutics is focused on commercializing innovative therapeutic products to address unmet patient needs, with its lead product ZELSUVMI™ approved in 2024 [12] Acquisition Details - The acquisition of Xeglyze allows Pelthos to commercialize the product worldwide without any future milestone or royalty payments to Hatchtech [2][3] - Xeglyze is a novel, FDA-approved pediculicide for treating head lice in patients aged 6 months and older, with a single 10-minute application [6][8] Product Information - Xeglyze demonstrates both ovicidal and lousicidal activity, offering a more effective treatment compared to existing products that require multiple applications [5][6] - The product's active ingredient, abametapir, inhibits metalloproteinases critical to lice egg development and survival [6] Market Context - Head lice infestations are common in the U.S., affecting an estimated 6 to 12 million children aged 3 to 11 annually, indicating a significant market opportunity for Xeglyze [4]